Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing, and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases. The Company's lead product candidates, bardoxolone methyl and RTA 408, are members of a class of small molecules called antioxidant inflammation modulators (AIMs). The Company's Bardoxolone methyl is an AIM, which targets the bioenergetic and inflammatory components of pulmonary hypertension (PH), which can improve functional capacity in patients suffering from certain forms of this disease. The Company's RTA 408 is a close structural analog of bardoxolone methyl that was developed to improve tissue distribution, including blood-brain barrier penetration.